Lung cancer epigenetics: Emerging biomarkers

Biomarkers in Medicine

Volumn 7, Issue 1, 2013, Pages 49-58

  Balgkouranidou, Ioanna ^a   Liloglou, Triantafillos ^b   Lianidou, Evi S ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

cell free circulating DNA; diagnosis; DNA methylation; non small cell lung cancer; prognosis; tumor biomarkers

Indexed keywords

APC PROTEIN; ARF PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DEATH ASSOCIATED PROTEIN KINASE; DNA; DNA METHYLTRANSFERASE 3A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; NEUROGENIN 2; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; TRANSCRIPTION FACTOR PITX2; TRANSCRIPTION FACTOR SOX17; TUMOR MARKER; UVOMORULIN;

CANCER PROGNOSIS; CIRCULATING TUMOR CELL; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; EARLY DIAGNOSIS; EPIGENETICS; GENE LOCUS; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; PROMOTER REGION; REVIEW;

DNA METHYLATION; DNA, NEOPLASM; EPIGENESIS, GENETIC; HUMANS; LUNG NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84873452165     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.111     Document Type: Review

References (122)

1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small-cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 83, 584-594 (2008).
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 75, 191-202 (1995).
3. Baylin SB. The cancer epigenome: its origins, contributions to tumorigenesis, and translational implications. Proc. Am. Thorac. Soc. 9(2), 64-65 (2012).
4. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 132 (Suppl. 3), 29S-55S (2007).
5. Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 31, 139-148 (2001).
6. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with case-control studies. Br. Med. J. 321, 323-329 (2000).
7. Henschke CI, Yankelevitz DF, Libby DM et al. Survival of patients with stage I lung cancer detected on CT screening. N. Engl. J. Med. 335, 1763-1771 (2006).
8. Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis 28, 507-518 (2007).
9. Markowitz SB, Miller A, Miller J et al. Ability of low-dose helical CT to distinguish between benign and malignant non calcified lung nodules. Chest 131(4), 1028-1034 (2007).
10. Baldwin DR, Duffy SW, Wald NJ, Page R, Hansell DM, Field JK. UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax 66(4), 308-313 (2011).
11. Field JK, Smith RA, Aberle DR et al. IASLC CT screening workshop 2011 participants. International association for the study of lung cancer computed tomography screening workshop 2011 report. J. Thorac. Oncol. 7(1), 10-19 (2012).
12. Raji OY, Duffy SW, Agbaje OF et al. Predictive accuracy of the Liverpool lung project risk model for stratifying patients for computed tomography screening for lung cancer: a case-control and cohort validation study. Ann. Intern. Med. 157(4), 242-250 (2012).
13. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol. 10, 1001-1010 (2009).
14. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2010).
15. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat. Clin. Pract. Oncol. 10, 588-599 (2008).
16. Duffy MJ. Role of tumor markers in patients with solid cancers: a critical review. Eur. J. Inern. Med. 18, 175-184 (2007).
17. Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA. The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis. Markers 23, 5-30 (2007).
18. Robertson KD. DNA methylation and human disease. Nat. Rev. Genet. 6, 597-610 (2005).
19. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 4, 143-153 (2000).
20. Esteller M, Silva JM, Dominguez G et al. Promoter hypermathylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92(7), 564-569 (2000).
21. Daskalos A, Logotheti S, Markopoulou S et al. Global DNA hypomethylation-induced DNp73 transcriptional activation in non-small-cell lung cancer. Cancer Lett. 300(1), 79-86 (2011).
22. Daskalos A, Nikolaidis G, Xinarianos G et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int. J. Cancer 124(1), 81-87 (2009).
23. Carvalho RH, Haberle V, Hou J et al. Genome-wide DNA methylation profiling of non-small-cell lung carcinomas. Epigenetics Chromatin 5(1), 9 (2012).
24. Ehrich M, Nelson MR, Stanssens P et al. Quantitative high-throughput analysis of DNA methylation patterns by base-specific cleavage and mass spectrometry. Proc. Natl Acad. Sci. USA 102(44), 15785-15790 (2005).
25. Ehrich M, Field JK, Liloglou T et al. Cytosine methylation profiles as a molecular marker in non-small cell lung cancer. Cancer Res. 66(22), 10911-10918 (2006).
26. Field JK, Liloglou T, Warrak S et al. Methylation discriminators in NSCLC identified by a microarray based approach. Int. J. Oncol. 27(1), 105-111 (2005).
27. Fukasawa M, Kimura M, Morita S et al. Microarray analysis of promoter methylation in lung cancers. J. Hum. Genet. 51(4), 368-374 (2006).
28. Hatada I, Fukasawa M, Kimura M et al. Genome-wide profiling of promoter methylation in human. Oncogene 25(21), 3059-3064 (2006).
29. Lewin J, Plum A, Hildmann T et al. Comparative DNA methylation analysis in normal and tumour tissues and in cancer cell lines using differential methylation hybridisation. Int. J. Biochem. Cell Biol. 39(7-8), 1539-1550 (2007).
30. Nelson HH, Marsit CJ, Christensen BC et al. Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling. Epigenetics 7(6), 559-566 (2012).
31. Rauch T, Li H, Wu X, Pfeifer GP. MIRA-assisted microarray analysis, a new technology for the determination of DNA methylation patterns, identifies frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res. 66(16), 7939-7947 (2006).
32. Selamat SA, Chung BS, Girard L et al. Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression. Genome Res. 22(7), 197-211 (2012).
33. Shames DS, Girard L, Gao B et al. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med. 3(12), e486 (2006).
34. Son JW, Jeong KJ, Jean WS et al. Genome-wide combination profiling of DNA copy number and methylation for deciphering biomarkers in non-small cell lung cancer patients. Cancer Lett. 311(1), 29-37 (2011).
35. Wang Y, Zhang D, Zheng W, Luo J, Bai Y, Lu Z. Multiple gene methylation of non-small-cell lung cancers evaluated with 3-dimensional microarray. Cancer 112(6), 1325-1336 9 (2008).
36. Knight LJ, Burrage J, Bujac SR et al. Epigenetic silencing of the endothelin-B receptor gene in non-small-cell lung cancer. Int. J. Oncol. 34(2), 465-471 (2009).
37. Verri C, Roz L, Conte D et al.; EUELC Consortium. Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. Am. J. Respir. Crit. Care Med. 179(5), 396-401 (2009).
38. Xinarianos G, McRonald FE, Risk JM et al. Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small-cell lung cancer. Hum. Mol. Genet. 15(13), 2038-2044 (2006).
39. Belinsky SA, Nikuja KJ, Palmisano WA et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891-11896 (1998).
40. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA 96, 12754-12759 (1999).
41. Palmisano WA, Divine KK, Saccomanno G et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954-5968 (2000).
42. Kim DS, Kim MJ, Lee JY, Kim YZ, Park JY. Aberrant methylation of E-cadherin and H-cadherin genes in non-small-cell lung cancer and its relation to clinicopathologic features. Cancer 110(12), 2785-2792 (2007).
43. Fischer JR, Ohnmacht U, Rieger N et al. Prognostic significance of RASSF1A promoter methylation on survival of non-small-cell lung cancer patients treated with gemcitabine. Lung Cancer 56(1), 115-123 (2007).
44. Grote HJ, Schmiemann V, Kiel S et al. Aberrant methylation of the adenomatous polyposis coli promoter 1A in bronchial aspirates from patients with suspected lung cancer. Int. J. Cancer 110(5), 751-755 (2004).
45. Begum S, Brait M, Dasgupta S et al. An epigenetic marker panel for detection of lung cancer using cell-free serum DNA. Clin. Cancer Res. 17(13), 4494-4503 (2011).
46. Tang X, Khuri FR, Lee JJ et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl Cancer Inst. 92(18), 1511-1516 (2000).
47. Shivapurkar N, Gazdar AF. DNA methylation based biomarkers in non-invasive cancer screening. Curr. Mol. Med. 10, 123-132 (2010).
48. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 62, 6645-6650 (2002).
49. Miyamoto K, Asada K, Fukutomi T et al. Methylation-associated silencing of heparin sulphate d-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22, 274-280 (2003).
50. Hagihara A, Miyamoto K, Futura J et al. Identification of 27 5́ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 23, 8705-8710 (2004).
51. Kaneda A, Takai D, Kaminishi M, Okochi E, Ushijima T. Methylation-sensitive representational difference analysis and its application to cancer research. Ann. NY Acad. Sci. 983, 131-141 (2003).
52. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat. Rev. Cancer 5, 223-231 (2005).
53. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821-9826 (1996).
54. Belinsky SA, Klinge DM, Dekker JD et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin. Cancer Res. 11, 6505-6511 (2005).
55. Fraga MF, Esteller M. DNA methylation. A profile of methods and applications Biotechniques 33(632), 636-649 (2002).
56. Liloglou T, Bediaga NG, Brown BR, Field JK, Davies MP. Epigenetic biomarkers in lung cancer. Cancer Lett. doi:10.1016/j. canlet.2012.04.018 (2012) (Epub ahead of print).
57. Nikolaidis G, Raji OY, Markopoulou S et al. DNA methylation biomarkers offer improved diagnostic efficiency in lung cancer. Cancer Res. 72(22), 5692-5701 (2012).
58. Ostrow KL, Hoque MO, Loyo M et al. Molecular analysis of plasma DNA for the early detection of lung cancer by quantitative methylation-specific PCR. Clin Cancer Res. 16(13), 3463-3472 (2010).
59. Styles T, Grant V. Good Clinical Laboratory Practice. British Association of Research Quality Assurance, UK (2011).
60. Walter K, Holcomb T, Janmario T et al. DNA methylation Profiling defines clinically relevant biological subsets of non-small-cell lung cancer. Clin. Cancer Res. 18(8), 2360-2373 (2012).
61. Schuffler P, Mikeska T, Waha A, Lengauer T, Bock C. MethMarker: user-friendly design and optimization of nege-specific DNA methylation assays. Genome Biol. 10(10), R105 (2009).
62. Machida EO, Brock MV, Hooker CM et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 66(12), 6210-6218 (2006).
63. Leng S, Do K, Yingling CM et al. Define a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin. Cancer Res. 18(12), 3387-3395 (2012).
64. De Fraipont F, Moro-Sibilot D, Michelland S, Brambilla E, Brambilla C, Favrot MC. Promoter methylation of genes in bronchial lavages: a market for early diagnosis of primary relapsing non-small-cell lung cancer? Lung Cancer 50(2), 199-209 (2005).
65. Kim H, Kwon YM, Kim JS et al. Tumor-specific methylation in bronchial lavage for early detection of non-small-cell lung cancer. J. Clin. Oncol. 22(12), 2363-2370 (2004).
66. Dietrich D, Kneip C, Raji O et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int. J. Oncol. 40(3), 825-832 (2012).
67. Hu YC, Sindrasky D, Ahrendt SA. Molecular detection approaches for smoking associated tumors. Oncogene 21(4), 7289-7297 (2002).
68. Simkin M, Abdalia M, El-Mogy M, Haj-Ahmad Y. Differences in the quantify of DNA found in the urine and saliva of smokers versus nonsmokers: implications for the timing of epigenetic events. Epigenomics 4(3), 343-352 (2012).
69. Han W, Wang T, Reilly AA, Keller SM, Spivack SD. Gene promoter methylation assayed in exhaled breath, with differences in smokers and lung cancer patients. Respir. Res. 10, 86 (2009).
70. Li L, Choi JY, Lee KM. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J. Epidemiol. 22(5), 384-394 (2012).
71. Levenson VV, Melnikov AA. DNA methylation as clinical useful biomarkers: light at the end of the tunel. Pharmaceuticals 5, 94-113 (2012).
72. Jen J, Wu L, Sindransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serums. Ann. NY Acad. Sci. 906, 8-12 (2000).
73. Wang L, Aakre JA, Jiang R et al. Methylation markers for small cell lung cancer in peripheral blood leukocyte DNA. J. Thorac. Oncol. 5(6), 778-785 (2010).
74. Atamaniuk J, Ruzicka K, Stuhlmeier KM, Karimi A, Eigner M, Mueller MM. Cell-free plasma DNA: a marker for apoptosis during hemodialysis. Clin. Chem. 52(3), 523-526 (2006).
75. Chimonidou M, Strati A, Tzitzira A et al. DNA methylation of tumor suppressor and metastasis suppressor genes in circulating tumor cells. Clin Chem Res. 57(8), 1169-1177 (2011).
76. Board RE, Knight L, Greystoke A et al. DNA methylation in circulating tumor DNA as a biomarker for cancer. Biomark. Insights 2, 307-319 (2007).
77. Caseira Cabral RE, Cabral Neto JB, da Costa Carvalho MG. Circulating DNA as a biomarker for early detection of cancer: a brief update with an emphasis on lung cancer. Open Lung Cancer J. 3, 38-44 (2010).
78. Lee TH, Montalvo L, Chrebtow V, Busch MP. Quantitation of genomic DNA in plasma and serum samples: higher concentrations of genomic DNA found in serum than in plasma. Transfusion 41, 276-282 (2001).
79. Thijssen MA, Swinkels DW, Ruers TJ, de Kok JB. Difference between free circulating plasma and serum DNA in patients with colorectal liver metastases. Anticancer Res. 22, 421-425 (2002).
80. Liggett T, Melnikov A, Yi QL et al. Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer 116, 1674-1680 (2010).
81. Liggett TE, Melnikov A, Yi Q et al. Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors. Gynecol. Oncol. 120, 113-120 (2011).
82. Kneip C, Schmidt B, Seegebarth A et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6(10), 1632-1638 (2011).
83. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small-cell lung cancer patients. Cancer Res. 59, 67-70 (1999).
84. Paliwal A, Vaissière T, Herceg Z. Quantitative detection of DNA methylation states in minute amounts of DNA from body fluids. Methods 52(3), 242-247. (2010).
85. Sterlacci W, Tzankov A, Veits L et al. A comprehensive analysis of p16 expression, gene status, and promoter hypermethylation in surgically resected non-small cell lung carcinomas. J. Thorac. Oncol. 6(10), 1649-1657 (2011).
86. Heller G, Zielinski CC, Zöchbauer-Müller S. Lung cancer: from single-gene methylation to methylome profiling. Cancer Metastasis Rev. 29(1), 95-107 (2010).
87. Topaloglu O, Hoque MO, Tokumaru Y et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin. Cancer Res. 10, 2284-2288 (2004).
88. Geng J, Sun J, Lin Q et al. Methylation status of NEYROG2 and NID2 improves the diagnosis of stage I NSCLC. Oncol. Lett. 3(4), 901-906 (2012).
89. Schiemann V, Bocking A, Kazimirek M et al. Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin. Cancer Res. 11, 7728-7734 (2005).
90. Grote HJ, Schiemann V, Geddert H et al. Methylation of RAS association domain family protein 1A as a biomarker of lung cancer. Cancer 108, 129-134 (2006).
91. Fujii M, Fujimoto N, Hiraki A et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma. Cancer Sci. 103(3), 510-514 (2012).
92. Van der Drift M, Prinsen C, Knuiman J, Janssen J, Dekhuijzen P.N, Thunnisen E. Diagnosis peripheral lung cancer: the additional value of RASSF1A methylation and KRAS mutation analyses in washings in non-diagnostic bronchoscopy. Chest 141(1), 169-175 (2012).
93. Schmidt B, Liebenberg V, Dietrich D et al. DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 10, 600 (2010).
94. Lu F, Zhang HT. DNA Methylation and non-small-cell lung cancer. Anat. Rec. 94, 1787-1795 (2011).
95. Brock MV, Hooker CM, Ota-Machida E et al. DNA methylation markers and early recurrence in stage I lung cancer. N. Engl. J. Med. 358, 1118-1128 (2008).
96. Yamamoto H, Toyooka S, Mitsudomi T. Impact of EGFR mutation analysis in non-small-cell lung cancer. Lung Cancer 63, 315-321 (2009).
97. Zhang Y, Wang H, Song G et al. Methylation of multiple genes as a candidate biomarker in non-small-cell lung cancer. Cancer Lett. 303 21-28 (2011).
98. Yang J, Shen Y, Liu B, Tong Y. Promoter methylation of BRMS1 correlates with smoking history and poor survival in non-small cell lung cancer patients. Lung Cancer 74, 305-309 (2011).
99. Lokk K, Vooder T, Kolde R et al. Methylation markers of early-stage non-small-cell lung cancer. PLoS One 7(6), e39813 (2012).
100. Dietrich D, Hasinger O, Liebenberg V, Field JK, Kristiansen G, Soltermann A. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome in non-small-cell lung cancer patients. Diagn. Mol. Pathol. 21, 93-104 (2012).
101. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and functions. Cell 116, 281-297 (2004).
102. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75, 843-854 (1993).
103. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259-269 (2006).
104. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 5, 522-531 (2004).
105. He L, He X, Lowe SW, Hannon GJ. MicroRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat. Rev. Cancer 7, 819-822 (2007).
106. Cho WC. OncomiRs. The discovery and progress of microRNAs in cancers. Mol. Cancer 6, 60 (2007).
107. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death and tumorigenesis. Br. J. Cancer 94(6), 776-780 (2006).
108. Hebert C, Norris K, Scheper MA et al. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 6(5) (2007).
109. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866 (2006).
110. Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753-3756 (2004).
111. Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
112. Johnson CD, Esquela-Kerscher A, Stefani G et al. The let-7 microRNA represses cell profileration pathways in human cells. Cancer Res. 67, 7713-7722 (2007).
113. Wang X, Ling C, Bai Y, Zhao J. MicroRNA-206 is associated with the invasion and metastasis of lung cancer. Anat. Rec. 294, 88-92 (2011).
114. Hayashita Y, Osada H, Tatematsu Y et al. A polycistronic microRNA cluster, miR-17-92 is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628-9632 (2005).
115. Heller G, Weinzierl M, Noll C et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin. Cancer Res. 18(6), 1619-1629 (2012).
116. Fazi F, Racanicchi S, Zardo G et al. Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein. Cancer Cell 12, 457-466 (2007).
117. Lujambio A, Ropero S, Ballestar E et al. Genetic unmasking of an epigenetically silencing microRNA in human cancer cells. Cancer Res. 67, 1424-1429 (2007).
118. Bueno MJ, Perez de Castro I, Gomez de Cedron M et al. Genetic and epigenetic silencing of microRNA-203 enchances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13, 496-506 (2008).
119. Brueckner B, Srtesemann C, Kuner R et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res. 67, 1419-1423 (2007).
120. Fabbri M, Garzon R, Cimmino A et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases EA and 3B. Proc. Natl Acad. Sci. USA 104, 15805-15810 (2007).
121. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13(10), 679-692 (2012).
122. Li KK, Li F, Li QS, Yang K, Jin B. DNA methylation as a target of epigenetic therapeutics in cancer. Anticancer Agents Med. Chem. (2012) (Epub ahead of print).